These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 22657952)

  • 21. Symptomatic remission and neurocognitive functioning in patients with schizophrenia.
    Hofer A; Bodner T; Kaufmann A; Kemmler G; Mattarei U; Pfaffenberger NM; Rettenbacher MA; Trebo E; Yalcin N; Fleischhacker WW
    Psychol Med; 2011 Oct; 41(10):2131-9. PubMed ID: 21426601
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A comparison of the CogState Schizophrenia Battery and the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Battery in assessing cognitive impairment in chronic schizophrenia.
    Pietrzak RH; Olver J; Norman T; Piskulic D; Maruff P; Snyder PJ
    J Clin Exp Neuropsychol; 2009 Oct; 31(7):848-59. PubMed ID: 19142774
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Opposite relationships between cannabis use and neurocognitive functioning in bipolar disorder and schizophrenia.
    Ringen PA; Vaskinn A; Sundet K; Engh JA; Jónsdóttir H; Simonsen C; Friis S; Opjordsmoen S; Melle I; Andreassen OA
    Psychol Med; 2010 Aug; 40(8):1337-47. PubMed ID: 19891810
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder.
    Houthoofd SA; Morrens M; Sabbe BG
    Clin Ther; 2008 Sep; 30(9):1565-89. PubMed ID: 18840365
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A double-blind study of combination of clozapine with risperidone in patients with schizophrenia: effects on cognition.
    Akdede BB; Anil Yağcioğlu AE; Alptekin K; Turgut TI; Tümüklü M; Yazici MK; Jayathilake K; Tunca Z; Göğüş A; Meltzer HY
    J Clin Psychiatry; 2006 Dec; 67(12):1912-9. PubMed ID: 17194269
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Executive and amnestic functions of a group of first-degree relatives of schizophrenic patients].
    Laurent A; d'Amato T; Naegele B; Murry P; Baro P; Foussard N; Spitz F; Dalery J
    Encephale; 2000; 26(5):67-74. PubMed ID: 11192806
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Persistent cognitive dysfunction despite clinical improvement in schizophrenia: a 10-year follow-up study.
    Shrivastava A; Johnston M; Shah N; Thakar M; Stitt L
    J Psychiatr Pract; 2011 May; 17(3):194-9. PubMed ID: 21586997
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of switching to long-acting injectable risperidone from oral atypical antipsychotics on cognitive function in patients with schizophrenia.
    Kim SW; Shin IS; Kim JM; Lee SH; Lee YH; Yang SJ; Yoon JS
    Hum Psychopharmacol; 2009 Oct; 24(7):565-73. PubMed ID: 19790174
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predictors of longitudinal changes in schizophrenia: the role of processing speed.
    Sánchez P; Ojeda N; Peña J; Elizagárate E; Yoller AB; Gutiérrez M; Ezcurra J
    J Clin Psychiatry; 2009 Jun; 70(6):888-96. PubMed ID: 19422757
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chronic temporal lobe epilepsy: a neurodevelopmental or progressively dementing disease?
    Helmstaedter C; Elger CE
    Brain; 2009 Oct; 132(Pt 10):2822-30. PubMed ID: 19635728
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Spatial working memory and problem solving in schizophrenia: the effect of symptom stabilization with atypical antipsychotic medication.
    Snyder PJ; Jackson CE; Piskulic D; Olver J; Norman T; Maruff P
    Psychiatry Res; 2008 Sep; 160(3):316-26. PubMed ID: 18579217
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neurocognitive functioning in patients with first-episode schizophrenia : results of a prospective 5-year follow-up study.
    Albus M; Hubmann W; Mohr F; Hecht S; Hinterberger-Weber P; Seitz NN; Küchenhoff H
    Eur Arch Psychiatry Clin Neurosci; 2006 Oct; 256(7):442-51. PubMed ID: 17031490
    [TBL] [Abstract][Full Text] [Related]  

  • 33. More evidence on proneurocognitive effects of add-on mirtazapine in schizophrenia.
    Stenberg JH; Terevnikov V; Joffe M; Tiihonen J; Tchoukhine E; Burkin M; Joffe G
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jun; 35(4):1080-6. PubMed ID: 21402120
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Memory performance and instruction effects in schizophrenia. A comparative study of chronic schizophrenic patients and healthy probands].
    Meissner F; Hacker W; Heilemann H
    Psychiatr Prax; 2001 May; 28(4):180-8. PubMed ID: 11428304
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cognitive dysfunctions in patients with obsessive-compulsive disorder compared to the patients with schizophrenia patients: relation to overvalued ideas.
    Kitis A; Akdede BB; Alptekin K; Akvardar Y; Arkar H; Erol A; Kaya N
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jan; 31(1):254-61. PubMed ID: 16914246
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of cognitive dysfunction in schizophrenia.
    Peuskens J; Demily C; Thibaut F
    Clin Ther; 2005; 27 Suppl A():S25-37. PubMed ID: 16198199
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A comparative study of the MATRICS and IntegNeuro cognitive assessment batteries.
    Silverstein SM; Jaeger J; Donovan-Lepore AM; Wilkniss SM; Savitz A; Malinovsky I; Hawthorne D; Raines S; Carson S; Marcello S; Zukin SR; Furlong S; Dent G
    J Clin Exp Neuropsychol; 2010 Nov; 32(9):937-52. PubMed ID: 20455131
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Disparate effects of first and second generation antipsychotics on cognition in schizophrenia - Findings from the randomized NeSSy trial.
    Veselinović T; Scharpenberg M; Heinze M; Cordes J; Mühlbauer B; Juckel G; Habel U; Rüther E; Timm J; Gründer G;
    Eur Neuropsychopharmacol; 2019 Jun; 29(6):720-739. PubMed ID: 30981585
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Gender differences in the neurocognitive components of depression].
    Sárosi A; Gonda X; Balogh G; Székely A; Sasvári M; Faludi G
    Neuropsychopharmacol Hung; 2008 Oct; 10(4):191-9. PubMed ID: 19213198
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neurocognitive and clinical predictors of functional outcome in patients with schizophrenia and bipolar I disorder at one-year follow-up.
    Tabarés-Seisdedos R; Balanzá-Martínez V; Sánchez-Moreno J; Martinez-Aran A; Salazar-Fraile J; Selva-Vera G; Rubio C; Mata I; Gómez-Beneyto M; Vieta E
    J Affect Disord; 2008 Aug; 109(3):286-99. PubMed ID: 18289698
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.